A pioneering cancer vaccine, developed through a collaboration between the University of Oxford and pharmaceutical giant Moderna, is set to undergo trials this summer.
The jab targets patients at high risk of colorectal (bowel) and ovarian cancer.
A pioneering cancer vaccine, developed through a collaboration between the University of Oxford and pharmaceutical giant Moderna, is set to undergo trials this summer.
The jab targets patients at high risk of colorectal (bowel) and ovarian cancer.